Ankylosing Spondylitis Pipeline Market Report 2021: Comprehensive Insights of Approx 40+ Companies and Pipeline Drugs - ResearchAndMarkets.com

·4 min read

The "Ankylosing Spondylitis- Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Ankylosing Spondylitis- Pipeline Insight, 2021," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Ankylosing Spondylitis pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Ankylosing Spondylitis R&D. The therapies under development are focused on novel approaches to treat/improve Ankylosing Spondylitis.

Ankylosing Spondylitis Emerging Drugs Chapters

This segment of the Ankylosing Spondylitis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ankylosing Spondylitis Emerging Drugs

Tofacitinib: Pfizer

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. It is in Preregistration Phase.

Bimekizumab: UCB Biopharma

Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F. Bimekizumab binds to and neutralizes IL-17A and IL-17F, preventing their interactions with the IL-17 receptors expressed on keratinocytes, fibroblast-like synoviocytes, endothelial cells, chondrocytes and osteoblasts. It is in Phase III of clinical trial.

Ankylosing Spondylitis: Therapeutic Assessment

This segment of the report provides insights about the different Ankylosing Spondylitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ankylosing Spondylitis

There are approx. 40+ key companies which are developing the therapies for Ankylosing Spondylitis. The companies which have their Ankylosing Spondylitis drug candidates in the most advanced stage, i.e. Preregistration include, Pfizer.

Phases

This report covers around 40+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Ankylosing Spondylitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

  • Oral

  • Intravenous

  • Subcutaneous

  • Intramuscular

  • Topical.

  • Molecule Type

Products have been categorized under various Molecule types such as:

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ankylosing Spondylitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Ankylosing Spondylitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ankylosing Spondylitis drugs.

Ankylosing Spondylitis Report Insights

  • Ankylosing Spondylitis Pipeline Analysis

  • Therapeutic Assessment

  • Unmet Needs

  • Impact of Drugs

Ankylosing Spondylitis Report Assessment

  • Pipeline Product Profiles

  • Therapeutic Assessment

  • Pipeline Assessment

  • Inactive drugs assessment

  • Unmet Needs

Key Questions

  • How many companies are developing Ankylosing Spondylitis drugs?

  • How many Ankylosing Spondylitis drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ankylosing Spondylitis?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ankylosing Spondylitis therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Ankylosing Spondylitis and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Fresenius Kabi

  • Shanghai Henlius Biotech

  • Pfizer

  • Fujifilm Kyowa Kirin Biologics

  • Hetero Biopharma

  • Bio-Thera Solutions

  • Amgen

  • CinnaGen

  • Zydus cadilla

  • Cadila Pharmaceuticals

  • Sandoz

  • Innovent Biologics

  • Fresenius Kabi

  • Torrent Pharmaceuticals

  • Cipla

  • Emcure Pharmaceuticals

  • Biogen

  • Boehringer Ingelheim

  • Zhejiang Hisun Pharmaceuticals

  • Biocad

  • Biocad

  • AbbVie

  • Mycenax Biotech

  • Celltrion

  • UCB Biopharma

  • Gilead Sciences

  • Amgen

  • Sun Pharma Global

  • Jiangsu HengRui Medicine Co., Ltd.

  • Izana Bioscience

  • Suzhou Zelgen Biopharmaceuticals

  • Iltoo Pharma

  • Kinevant Sciences

  • Qyuns Therapeutics

  • Akeso Biopharma

  • Nimbus Therapeutics

  • Enzene Biosciences

  • Xbrane Biopharma

  • Dice molecules

Key Products

  • MSB11022

  • HLX03

  • Abrilada

  • Hulio

  • Pamera

  • Qletli

  • Solymbic

  • Cinnora

  • Adaly

  • Cadalimab

  • Halimatoz

  • Sulinno

  • Kromeya

  • Adfrar

  • Plamumab

  • Envira

  • Imraldi

  • Cyltezo

  • Adalimumab biosimilar

  • BCD-085

  • BCD-055

  • Upadacitinib

  • Tofacitinib

  • Etanercept biosimilar

  • CT-P17

  • Bimekizumab

  • Filgotinib

  • Apremilast

  • Tildrakizumab

  • SHR0302

  • Namilumab

  • Jaktinib

  • Interleukin 2

  • KIN-1901

  • QX002N

  • AK111

  • TYK2

  • Adalimumab biosimilar

  • Xcimzane

  • DNA-encoded library (DEL) technology

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ymd2hb

View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005436/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900